Back to top

immuno-therapy: Archive

Zacks Equity Research

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

LGNDNegative Net Change ANIPNegative Net Change ADMANegative Net Change ENLVNegative Net Change